Baxter’s Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA’s Approval for Diabetes Mellitus

 Baxter’s Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA’s Approval for Diabetes Mellitus

Baxter’s Myxredlin Ready-To-Use Insulin for IV Infusion Receives FDA’s Approval for Diabetes Mellitus

Shots:

  • The US FDA has granted approval to Myxredlin as the first ready-to-use insulin for IV infusion in the hospital with an extended shelf-life of 30 days @25◦C or 24 mos. if refrigerated @2-8◦C
  • Myxredlin utilizes Baxter’s Galaxy container technology which is a non-PVC and non-DEHP system enabling premixed medicines to have a longer shelf life at room temperature
  • Myxredlin (insulin human in 0.9% sodium chloride injection) is available in a standardized concentration of 100 units/100 mL in a flexible plastic container indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus

Click here to read full press release/ article | Ref: Baxter | Image: Baxter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post